5 Tips about Sifalimumab You Can Use Today
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze to evaluate numerous intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Most important demo targets were to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyo